Stereotactic Body Radiotherapie for Oligoprogressive Disease in Androgen-Suppressed Prostaatkanker: Primary Endpoint Analyse of the TRAP Trial
Optimal management of oligoprogressive prostaatkanker while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiotherapie (SBRT) in this setting.
Abstract (original)
Optimal management of oligoprogressive prostate cancer while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiation therapy (SBRT) in this setting. The objective of this phase 2 prospective, nonrandomized, single-arm trial was to determine if local control of oligoprogressive disease with SBRT can delay further progression by >4 months, postponing time to next therapy.
Dit artikel is een samenvatting van een publicatie in Int J Radiation Oncology. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.1016/j.ijrobp.2025.02.046